Amgen Stock News

David V. Smith to join Board of Directors Elizabeth Smith and Richard Lopez, M.D., to join Scientific Advisory Board ALAMEDA, Calif., Jan. 06, 2022 (GLOBE NEWSWIRE) -- Acepodia , a clinical-stage biotechnology company developing first-in-class cell therapies with its unique Antibody-Cell Conjugation (ACC) platform technology to address gaps in cancer care, today announced it has appointed David V. Smith to its Board of Directors and Elizabeth Smith and Richard Lopez, M.D., to its Scientific Advisory Board. "Following our recent Series C funding milestone, we are pleased to bring on a strong roster of industry leaders who bring deep expertise across allogeneic cell therapy development, regulatory affairs, and finance, to help us bring forth next-generation cell therapies for the people who need them most," said Sonny Hsiao, Ph.D., chief executive officer, president and co-founder of Acepodia. David V. Smith Mr. Smith currently serves as a member of the Board of Directors at Codexis and Neurelis and most recently served as Executive Vice President and Chief Financial Officer of Five Prime Therapeutics, acquired by Amgen in 2021.

Amgen Inc. AMGN, -0.37% announced Thursday a research collaboration with privately held Generate Biomedicines to discover and create protein therapeutics, which could lead to a potential payment to Ge

These seven pharmaceutical stocks could create lucrative opportunities in the new year The post 7 Pharmaceutical Stocks That Could Make You Rich appeared first on InvestorPlace. More From InvestorPlac

"There are a few comeback stories in the dogs of the Dow, but for the most part I don't expect these dogs to have their day in 2022," the "Mad Money" host said.

Amgen Inc. was downgraded at BofA Securities, with analyst Geoff Meacham saying he believes the lingering COVID-19 headwinds and net pricing pressures that weighed on the biotechnology company in 2021 are likely to continue this year. Meacham cut his rating to neutral, after being at buy since March 2020, and lowered his stock price target to $255 from $285. The stock was little changed in afternoon trading, after trading down as much as 1.5% and up as much as 0.9% in intraday trading. "Looking to 2022, we''d argue that growth skepticism is likely to persist until Amgen demonstrates a clear return to strong, volume-driven revenue upside for a number of key franchises including Otezla," Meacham wrote in a note to clients. He had previously expected Otezla and the company''s biosimilars franchise to drive growth acceleration in 2022, but he now thinks that a return to substantial growth may be delayed to later in 2022 or in early 2023. The stock has gained 7.6% over the past three months, while the Dow Jones Industrial Average , which has Amgen as a component, has tacked on 7.5%.

Amgen <> was downgraded by Bank of America to Neutral from Buy with a price target of $255, down from $285.BofA analyst Geoff Meacham said the stock has underwhelmed in 2021 due

I present my top 10 High Yield dividend stocks that are poised to offer strong future returns. The annualized rate of return for this watchlist is 39.18% over the past 14 months.

Amgen Inc. AMGN, +0.03% was downgraded at BofA Securities, with analyst Geoff Meacham saying he believes the lingering COVID-19 headwinds and net pricing pressures that weighed on the biotechnology co

The U.S. Food and Drug Administration recently approved Amgen's Otezla to treat all severity levels of plaque psoriasis.

The decades-old income-and-value strategy, the Dogs of the Dow, will try to bounce back in 2022. Here are this year's 10 members.

Here are the newest stocks to join the portfolio for those using this easy-to-follow strategy.

Stocks Analysis by Zacks Investment Research covering: Amgen Inc. Read Zacks Investment Research''s latest article on Investing.com

Amgen (AMGN) closed at $226.69 in the latest trading session, marking a +0.76% move from the prior day.